Stock Analysis
Abivax S.A. (ABVX) Stock Analysis
Abivax S.A. (ABVX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Abivax S.A. (ABVX) currently has an AIQ Score of 35/100, indicating a bearish setup. Risk is the strongest factor at 37/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
ABVX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $87.58 |
| AIQ Score | 35/100 |
| Overall View | Bearish |
| Technical Analysis Consensus | Strong Sell |
| Market Cap | $6.98B |
| P/E Ratio (TTM) | -16.79 |
| Forward P/E | — |
| EPS (Q2 FY2026) | -$1.47 |
| Revenue (Q2 FY2026) | $0 |
| Dividend Yield (TTM) | 0.00% |
| Beta | 1.18 |
| Volume | 698.95K |
| 52-week range | $69.81-$148.83 |
| RSI 14 | 45.5 |
| 50-Day SMA | $94.85 |
| 200-Day SMA | $112.57 |
| Analyst Price Target | $141.33 |
| Next Earnings | Dec 21, 2026 |
ABVXAbivax S.A.
Healthcare / Biotechnology
Low Priority
In Line With Peers
Latest quote
- Momentum34
- Value—
- Quality35
- Risk resilience37
- Sentiment—
ABVX Stock Analysis Summary
Abivax S.A. (ABVX) currently has an AIQ Score of 35/100, indicating a bearish setup. Risk resilience is the strongest factor at 37/100. Momentum is the weakest current factor at 34/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bearish regime, ABVX has AIQ Score of 35/100 with Risk resilience base of 37/100 and fading Momentum at 34/100. Wait for component alignment before adding exposure.
Healthcare · -2.90% stock move · ABVX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is ABVX Bullish or Bearish Right Now?
ABVX currently has a bearish overall setup. Risk Resilience is the strongest factor at 37/100, while Momentum is weakest at 34/100. The current evidence suggests a bearish setup.
- - Analyst target implies +61.38% upside from the latest quote.
- - Momentum is weak at 34/100.
- - Risk Resilience is weak at 37/100.
- - Price is -22.20% below its 200-day SMA.
- - Technical consensus has more sell votes than buy votes (31 vs 7).
Current Consensus
ABVX's Technical Analysis Consensus is currently Strong Sell, with 7 buy, 8 neutral, and 31 sell votes. ABVX's 14-day RSI is 45.5, which places the stock in a neutral momentum range. ABVX's beta is 1.18, indicating market sensitivity broadly in line with the market.
What Changed in ABVX?
The largest recent change in ABVX is Momentum moving up by 3.0 points over the available 7-day comparison window. Risk Resilience remains the strongest visible factor.
What Would Change the ABVX Outlook?
The current bearish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
ABVX Decision Framework
Public evidence layers, setup checks, and risk context for Abivax S.A..
Abivax S.A. (ABVX) Stock Analysis
Abivax S.A. has an AIQ Score of 35/100 in a Bearish regime. Risk is strongest at 37/100. Beta is 1.18, above market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | ABVX is in a Bearish AIQ regime with score 35/100. |
| Signal Conflict | The primary conflict is that risk leads at 37/100 while momentum lags at 34/100. |
| Factor Evidence | Momentum 34/100 · Quality 35/100 · Risk 37/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Risk is the strongest factor at 37/100.
Momentum is 34/100 and RSI (14) is 45.5.
ABVX is in a Bearish regime at 35/100.
Risk factor is 37/100 with beta 1.18 and annual volatility 86.44%.
Current conflict: risk leads at 37/100 while momentum lags at 34/100.
ABVX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
ABVX Fundamentals
ABVX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
ABVX Technical Analysis
ABVX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
ABVX Stock Catalysts
Track ABVX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
ABVX Dividend Analysis
ABVX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
ABVX Financial Data
ABVX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
ABVX Risk Analysis
ABVX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
ABVX Stock News
ABVX stock news, market tone, recent headlines, and catalyst context.
ABVX vs Biotechnology Peers
Current peer cohort: ABVX · ADMA · AGIO · ALMS · AMLX. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| ABVX Current stock | 35/100 | — | 34/100 | 37/100 | 0.24 | 86.44% | Current |
| ADMA ADMA Biologics, Inc. | 78/100 | 80/100 | 91/100 | 56/100 | -0.01 | 58.93% | ABVX vs ADMA |
| AGIO Agios Pharmaceuticals, Inc. | 56/100 | 52/100 | 61/100 | 47/100 | 0.07 | 79.96% | ABVX vs AGIO |
| ALMS Alumis Inc. | 20/100 | — | 13/100 | 20/100 | 0.65 | 137.60% | ABVX vs ALMS |
| AMLX Amylyx Pharmaceuticals, Inc. | 78/100 | — | 90/100 | 48/100 | 1.35 | 87.03% | ABVX vs AMLX |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for ABVX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Jun 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching ABVX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for ABVX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
ABVX Stock FAQ
What is ABVX stock price today?
Abivax S.A.'s current stock price is $87.58. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is ABVX bullish or bearish right now?
ABVX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is ABVX's market cap?
ABVX's market cap is $6.98B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is ABVX's current P/E ratio?
ABVX's current P/E ratio is -16.79 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is ABVX's RSI?
ABVX's 14-day RSI is 45.5 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is ABVX above its 50-day and 200-day moving averages?
ABVX is -7.66% from its 50-day SMA and -22.20% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is ABVX's next earnings date?
ABVX's next earnings date is currently listed as Dec 21, 2026. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does ABVX pay a dividend?
ABVX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.